Calidi Biotherapeutics Inc.

Stock Chart, Company Information, and Scan Results

$0.27(as of Apr 13, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Calidi Biotherapeutics Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$0.27
Ticker SymbolCLDI
ExchangeNyse Mkt
SectorHealthcare
IndustryBiotechnology
Employees29
CountyUSA
Market Cap$2.8M

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Calidi Biotherapeutics Inc. In Our Stock Scanner

As of Apr 14, 2026
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.